Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage
One of the Danish drugmaker’s partnered patient organizations did not disclose ties to Novo Nordisk in promotional material for obesity treatment.
by christian bundgaard, translated by daniel pedersen
Shortly after the UK Association of the British Pharmaceutical Industry (ABPI) suspended the Danish drugmaker’s membership for two years for marketing violations, Novo Nordisk is hit with allegations of more stealth marketing.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
